WHIte MAtter Hyperintensity Shape and Glymphatics
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Aug 23, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The WHIte MAtter Hyperintensity Shape and Glymphatics trial is studying the relationship between certain brain changes and dementia, particularly focusing on a condition called cerebral small vessel disease (SVD). This research aims to understand how waste products build up in the brain and how this might contribute to cognitive decline or dementia. By using advanced MRI technology, the trial hopes to identify different shapes of brain lesions that could indicate various underlying problems related to SVD. This could help researchers find new ways to understand and potentially treat dementia.
To participate in this study, individuals must be at least 65 years old, be fluent in Dutch, and be able to undergo an MRI scan. It's important to note that those with certain medical conditions, such as severe neurological diseases or those who are unable to provide consent, will not be eligible. Participants can expect to undergo brain imaging and contribute to important research that may lead to better understanding and treatment of dementia in the future. The study is currently recruiting participants at specific memory and geriatric clinics in Leiden.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admitted to the memory or the geriatric clinic of the LUMC, the Alrijne Hospital Leiden or the Haga Hospital the Hague
- • From 65 years of age
- • Eligible for MRI
- • Native-level Dutch speaker
- Exclusion Criteria:
- • Claustrophobia
- • Contraindications for MRI such as metal implants and pacemaker
- • Use of benzodiazepines
- • Initiated treatment with antidepressants less than 6 weeks prior to inclusion
- • Not being able to provide written informed consent (assessed by the treating physician)
- • Individuals that have been declared mentally incapacitated
- • Other severe neurological disease besides dementia related
- • Cognitive impairment due to known other neurological disease
- • Previous brain surgery
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leiden, , Netherlands
Patients applied
Trial Officials
Jeroen de Bresser, MD, PhD
Principal Investigator
Leiden University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported